Pharmaceutical giants Eli Lilly and Company & Novo Nordisk A/S face challenges in the obesity market despite promising data.

Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in a clinical trial funded by Lilly.

Adults taking Zepbound lost 47% more weight on average than those taking Wegovy, according to clinical trial data from ...

Labor and delivery units are losing money and struggling to find staff, in rural areas and large cities alike.

President Joe Biden wants Medicare and Medicaid to cover weight-loss drugs, a proposal that would expand access to the costly ...

Eli Lilly said its drug Zepbound led to greater weight reduction than rival Novo Nordisk's Wegovy in a head-to-head ...

Eli Lilly said its weight loss drug Zepbound led to 47% greater weight reduction than rival medicine Wegovy, made by Novo ...

Chang W. Lee/The New York Times Wednesday's protest at the National Assembly. Moving furniture that was used to barricade the entrance to the National Assembly overnight. Kim Hong-Ji/Reuters ...

LSU football was handed a gut-wrenching loss in Week 11 by No. 11 Alabama, a loss that significantly impacted its College Football Playoff odds and path. Already dealing with a small room for ...

Despite following all recommended screenings, Regina Barzilay, PhD, was diagnosed with breast cancer. Discover how this Health Hero’s experience led to an AI system that improves breast cancer ...